Overview

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and one of the leading causes of cancer-related death worldwide. Chronic hepatitis B virus (HBV) infection is the single most prevalent etiological factor globally, accounting for approximately 50 to 55% of all HCC cases. The progression from chronic HBV infection to HCC is not inevitable, but it is strongly modulated by virological, biochemical, and demographic factors that can be measured non-invasively at the point of care.

The REACH-B score (Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV) is a validated, quantitative risk-stratification tool that estimates the 10-year absolute risk of HCC in non-cirrhotic adults with chronic HBV infection. Developed from the landmark REVEAL-HBV prospective cohort study in Taiwan and subsequently validated across multiple Asian and non-Asian populations, the REACH-B score synthesizes five independently predictive variables into a single numerical risk estimate ranging from 0 to 17 points. It enables clinicians to identify patients at low, intermediate, and high risk for HCC development over a 10-year horizon, informing decisions about HBV surveillance intensity, antiviral therapy initiation, and patient counseling.

The Burden of HBV-Related HCC

Global Epidemiology

Approximately 296 million people live with chronic HBV infection globally (defined as hepatitis B surface antigen, HBsAg, positivity for more than six months). Prevalence is highest in sub-Saharan Africa (5 to 8%), East Asia (5 to 8%), and the Pacific Islands (10 to 20%), with intermediate prevalence in South and Southeast Asia, the Middle East, and Eastern Europe. In hyperendemic regions, vertical (mother-to-child) transmission and horizontal transmission in early childhood are the dominant routes; in low-prevalence Western countries, sexual contact and parenteral exposure are more common acquisition routes.

The lifetime risk of HCC in individuals with chronic HBV infection is estimated at 10 to 25% in men and 3 to 8% in women from high-prevalence populations, depending on HBeAg status, viral load, presence of cirrhosis, family history of HCC, and co-existing liver disease. HBV-related HCC frequently arises in the absence of cirrhosis, accounting for 30 to 40% of HBV-HCC cases in some series, and this non-cirrhotic pathway distinguishes HBV from other major HCC etiologies such as hepatitis C virus (HCV) and nonalcoholic steatohepatitis (NASH), where cirrhosis is almost universally present at the time of HCC diagnosis.

HBV Carcinogenesis

HBV promotes hepatocarcinogenesis through both indirect (inflammatory, fibrotic) and direct (viral integration, oncogene activation) mechanisms:

• Viral integration: HBV DNA integrates into the host hepatocyte genome early in infection. Integration events can activate proto-oncogenes (including TERT, MLL4, and CCNE1) and disrupt tumor suppressor genes, directly driving malignant transformation independent of cirrhosis or ongoing inflammation.
• HBx protein: The HBV X protein (HBx) is a viral transactivator that stimulates cell proliferation, inhibits apoptosis, impairs DNA repair, and modulates epigenetic regulation, all of which promote hepatocyte malignant transformation. HBx is expressed at high levels during active viral replication.
• Chronic inflammation and fibrosis: Persistent immune-mediated hepatocyte injury drives a cycle of hepatocyte necrosis, regeneration, fibrosis, and cirrhosis. Oxidative stress during active hepatitis promotes DNA mutations. Cirrhosis itself is the dominant HCC risk state in HBV infection, with annual HCC incidence of 2 to 8% in cirrhotic HBV patients versus 0.1 to 0.4% in non-cirrhotic HBV carriers.
• Viral replication level: High serum HBV DNA is the most consistently replicated independent virological predictor of HCC across prospective cohorts. The REVEAL-HBV study established a strong dose-response relationship between HBV DNA level and HCC risk that underpins the REACH-B score.

The REVEAL-HBV Cohort Study

The Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL-HBV) study is a community-based prospective cohort study conducted in Taiwan. Enrolled between 1991 and 1992, the cohort comprised 3,653 HBsAg-positive adults aged 30 to 65 years who were free of cirrhosis and HCC at baseline. Participants underwent standardized clinical evaluation including serum HBV DNA quantification (by solution hybridization assay), HBeAg testing, liver biochemistry, and abdominal ultrasonography at baseline, with regular follow-up surveillance for HCC development.

The REVEAL-HBV study generated a series of landmark publications establishing:

• A direct, independent, and log-linear relationship between baseline serum HBV DNA level and the risk of HCC over a 10-year follow-up, even after adjustment for HBeAg status, ALT level, sex, and age (Chen et al., NEJM 2006).
• An independent association between HBeAg positivity and HCC risk beyond the contribution of HBV DNA level.
• The predictive value of serum ALT level (as a surrogate of hepatocyte injury) for HCC risk, particularly when elevated above the upper limit of normal.
• A significant interaction between sex and age as determinants of HCC incidence, with male sex and increasing age each independently increasing risk.

The REACH-B score was derived from a multivariate analysis of these REVEAL-HBV data by Yang and colleagues (Lancet Oncology, 2011), selecting variables with independent predictive value and assigning integer point values proportional to their hazard ratios from Cox regression modeling.

REACH-B Score: Variables and Scoring

The REACH-B score is calculated from five variables measurable at a routine clinical encounter. No liver biopsy, imaging, or specialized testing is required beyond standard HBV monitoring.

Variable	Category	Points
Sex	Female	0
	Male	2
Age (years)	30–34	0
	35–39	1
	40–44	2
	45–49	3
	50–54	4
	55–59	5
	60–65	6
ALT Level (U/L)	<15	0
	15–44	1
	45–300	2
	>300	3
HBeAg Status	Negative	0
	Positive	2
Serum HBV DNA (copies/mL)	<300 (undetectable)	0
	300–9,999	1
	10,000–99,999	2
	100,000–999,999	3
	≥1,000,000	4

Total score range: 0 to 17 points.

Unit Conversion Note for HBV DNA

Modern laboratories report HBV DNA in IU/mL (International Units per milliliter). The REACH-B score was originally derived using copies/mL. The conversion factor is approximately 1 IU/mL = 5.6 copies/mL (varies slightly by assay). The corresponding IU/mL thresholds are therefore approximately:

• <300 copies/mL ≈ <55 IU/mL (undetectable on most modern assays)
• 300–9,999 copies/mL ≈ 55–1,800 IU/mL
• 10,000–99,999 copies/mL ≈ 1,800–17,900 IU/mL
• 100,000–999,999 copies/mL ≈ 17,900–179,000 IU/mL
• ≥1,000,000 copies/mL ≈ ≥179,000 IU/mL (often reported as ≥2 × 10⁵ IU/mL at clinical decision thresholds)

When modern IU/mL results are available, a commonly used clinical approximation is to multiply IU/mL by 5 to estimate copies/mL, then apply the REACH-B thresholds above.

10-Year HCC Risk by REACH-B Score

Each integer REACH-B score corresponds to a specific estimated 10-year cumulative risk of HCC derived from the REVEAL-HBV actuarial survival analysis:

REACH-B Score	Estimated 10-Year HCC Risk (%)	Risk Category
0	0.0	Low
1	0.1
2	0.2
3	0.3
4	0.4
5	0.5
6	1.1	Intermediate
7	1.7
8	2.6
9	4.1
10	6.2
11	9.4
12	14.2	High
13	21.1
14	30.8
15	43.1
16	57.8
17	69.7

Risk categories are commonly stratified as:

• Low risk (score 0–5): 10-year HCC risk <1%. Standard surveillance with ultrasound every 6 to 12 months per current guidelines; antiviral therapy decision based on virological and biochemical thresholds.
• Intermediate risk (score 6–11): 10-year HCC risk 1 to 9%. Vigilant surveillance; stronger consideration for antiviral therapy even at lower ALT thresholds if HBV DNA is elevated.
• High risk (score 12–17): 10-year HCC risk >10%. Intensive HCC surveillance; urgent antiviral therapy initiation; discussion of HCC screening interval shortening to every 3 to 4 months with ultrasound or addition of alpha-fetoprotein (AFP) and/or cross-sectional imaging (CT or MRI) per institutional protocol.

Detailed Variable Analysis

Sex: Male (+2 points)

Male sex is one of the most consistently replicated risk factors for HCC across all etiologies, including HBV. In the REVEAL-HBV cohort, male sex was associated with a hazard ratio of approximately 3.0 for HCC incidence after adjustment for other variables. Proposed biological mechanisms include:

• Sex hormone differences: Androgens (testosterone and dihydrotestosterone) promote hepatocyte proliferation and may enhance HBV replication. The androgen receptor (AR) activates viral transcription from the HBV promoter. Conversely, estrogens appear hepatoprotective, partly through induction of antiviral immune responses and inhibition of AR signaling.
• Immune response differences: Women mount stronger innate and adaptive immune responses to HBV, leading to higher rates of spontaneous HBsAg clearance and lower chronic carrier rates. Among those who do develop chronic infection, female sex is associated with lower HBV DNA levels and lower rates of immune-active hepatitis.
• Behavioral differences: Men in East Asia have historically higher rates of alcohol consumption and tobacco use, both established HCC co-risk factors, though the sex differential in REVEAL-HBV persisted after accounting for these cofactors.

Age: 0–6 points

Increasing age is a linear predictor of HCC risk in chronic HBV infection, reflecting cumulative duration of viral exposure, progressive hepatic fibrosis accumulation, accumulation of carcinogenic DNA mutations, waning immunosurveillance of malignant hepatocytes with aging, and increasing HBV DNA integration burden. The REACH-B score is validated for adults aged 30 to 65; it does not apply to patients under 30 or over 65.

In children and young adults with chronic HBV, HCC is rare (though not absent, particularly in hyperendemic settings with perinatal acquisition). In adults over 65, the risk of HCC continues to rise, but the REVEAL-HBV cohort did not include this age group at baseline, and the REACH-B point assignment for age does not extend beyond 65. Clinicians managing older HBV patients should recognize that REACH-B may underestimate risk in this group.

ALT Level: 0–3 points

Alanine aminotransferase (ALT) is the standard biochemical surrogate of hepatocyte injury in HBV infection. Elevated ALT reflects active immune-mediated hepatocellular necrosis, which drives inflammation, fibrosis, and regenerative hyperplasia, all of which promote carcinogenesis. In the REVEAL-HBV cohort, ALT above the upper limit of normal was independently associated with HCC after adjustment for HBV DNA and HBeAg.

The REACH-B score uses a more granular ALT categorization than a simple normal/abnormal dichotomy, recognizing that:

• Very low ALT (<15 U/L) indicates minimal ongoing hepatocyte injury, typically seen in inactive HBV carriers, and carries the lowest HCC risk.
• ALT in the 15 to 44 U/L range (broadly "normal" by older laboratory standards, though current AASLD guidelines suggest that truly normal ALT may be ≤35 U/L in men and ≤25 U/L in women) represents a low-to-intermediate risk state.
• ALT 45 to 300 U/L indicates active hepatitis and carries meaningfully higher HCC risk than normal ALT, even when HBV DNA is accounted for.
• ALT >300 U/L (more than 6 to 7 times the upper limit of normal) indicates severe acute or subacute hepatocellular injury, potentially signaling a hepatitis flare, which in chronic HBV infection is associated with accelerated fibrosis and heightened HCC risk.

Clinicians should note that a single ALT measurement may not reflect the long-term ALT trajectory. Patients with fluctuating ALT (characteristic of HBeAg-negative chronic HBV) may score differently at different time points, and serial assessments over 6 to 12 months more accurately capture risk than a single snapshot.

HBeAg Status: Negative (0) vs. Positive (+2)

Hepatitis B e antigen (HBeAg) is a secreted protein derived from the HBV precore/core gene, whose presence in serum traditionally indicates active viral replication and high infectivity. HBeAg-positive patients generally have higher HBV DNA levels and more active hepatitis, though HBeAg positivity retains independent predictive value for HCC even after adjustment for HBV DNA level in multivariate analyses.

The HBeAg contribution to HCC risk likely operates through multiple mechanisms:

• Marker of immune tolerance phase: Perinatally infected individuals may remain HBeAg-positive for decades in an immune-tolerant phase with very high HBV DNA but normal or minimally elevated ALT. During this phase, progressive HBV DNA integration and direct viral oncogenesis may accumulate even in the absence of significant inflammation.
• HBeAg-specific immune effects: HBeAg may suppress innate immune responses and promote immune tolerance to HBV, allowing sustained viral replication and ongoing hepatocellular damage.
• Correlation with high-risk viral variants: HBeAg positivity is associated with wild-type precore/core sequences that have been linked to higher viral fitness and possibly greater oncogenic potential.

HBeAg seroconversion (loss of HBeAg with development of anti-HBe antibodies) generally marks a transition to lower viral replication and reduced hepatitis activity, but it does not eliminate HCC risk, particularly in older patients with pre-existing liver damage or in those who undergo HBeAg seroconversion with subsequent HBeAg-negative chronic hepatitis B driven by precore mutant virus.

HBV DNA Level: 0–4 points

Serum HBV DNA level is the most powerful virological predictor of HCC in chronic HBV infection, and the dose-response relationship established by the REVEAL-HBV study is the foundational evidence supporting HBV DNA-guided antiviral therapy decisions. In the original REVEAL-HBV analysis (Chen et al., NEJM 2006), HBV DNA levels <300 copies/mL were associated with a cumulative 10-year HCC incidence of 1.3%, compared with 14.9% for DNA levels of 10⁶ copies/mL or higher, with a monotonically increasing risk across the intermediate strata.

This gradient is preserved in the REACH-B score, where each 1-log increment in HBV DNA above the lowest category contributes approximately 1 additional point. The biological mechanisms are:

• Viral replication and genome integration frequency: Higher viral load correlates with higher rates of HBV DNA integration events per hepatocyte generation, increasing the probability of oncogenic insertional mutagenesis.
• Sustained hepatocellular injury: High viral replication drives ongoing immune-mediated hepatocyte death and regeneration, accelerating the accumulation of somatic mutations and fibrosis progression.
• HBx expression level: High HBV DNA corresponds to high HBx transcription, amplifying all HBx-mediated oncogenic signaling pathways.
• Immune evasion: Very high viral loads may overwhelm and exhaust HBV-specific T cell responses, allowing persistent unchecked viral replication and hepatocellular damage.

Clinical Applications of the REACH-B Score

HCC Surveillance Stratification

All major hepatology guidelines (AASLD, EASL, APASL, KASL) recommend HCC surveillance in chronic HBV carriers, but differ in the degree to which risk stratification should guide surveillance intensity. The REACH-B score provides objective, evidence-based risk quantification to support individualized surveillance planning:

• Low-risk patients (score 0–5): Standard 6-monthly abdominal ultrasound with or without AFP (per guideline preference) is appropriate. The absolute 10-year risk is sufficiently low that intensified surveillance is unlikely to be cost-effective.
• Intermediate-risk patients (score 6–11): Standard 6-monthly ultrasound is the minimum. In patients with score 9 to 11, some specialists advocate for addition of AFP, des-gamma-carboxyprothrombin (DCP/PIVKA-II), or AFP-L3 fraction as complementary biomarkers to improve sensitivity.
• High-risk patients (score 12–17): Enhanced surveillance is warranted. Options include shortening the ultrasound interval to every 3 to 4 months, adding serum AFP and/or DCP measurements, or performing periodic cross-sectional imaging (multiphase CT or gadoxetate-enhanced MRI), particularly if ultrasound quality is suboptimal due to obesity, cirrhosis, or steatosis.

Antiviral Therapy Decision Support

Nucleos(t)ide analog (NA) therapy with entecavir or tenofovir (TDF or TAF) suppresses HBV replication to undetectable levels, reduces hepatic inflammation, reverses fibrosis, and decreases, though does not eliminate, HCC risk. Current treatment thresholds (HBV DNA, ALT, fibrosis stage) are defined by guideline consensus, but the REACH-B score can supplement these criteria:

• A high REACH-B score in a patient who does not yet meet formal treatment thresholds (e.g., a patient with HBV DNA 50,000 copies/mL and persistently normal ALT) may prompt closer monitoring and lower threshold for initiating therapy, in shared decision-making with the patient.
• The REACH-B score can quantify the magnitude of HCC risk reduction achievable with antiviral therapy by comparing the pre-treatment score (incorporating actual HBV DNA) against the expected score if HBV DNA were suppressed to undetectable (<300 copies/mL). This "risk delta" can be a compelling patient education tool.
• In patients already on antiviral therapy, a re-calculated REACH-B score using the on-treatment HBV DNA (typically undetectable with effective NA therapy) reflects residual HCC risk, recognizing that long-term NA therapy reduces but does not fully normalize HCC risk, particularly in patients with pre-existing cirrhosis or older age.

Patient Counseling and Shared Decision-Making

Quantitative risk communication has been shown to improve patient understanding and adherence in chronic disease management. Presenting a 10-year HCC risk as an absolute percentage (e.g., "your current 10-year risk of liver cancer is approximately 14%") is more actionable than qualitative descriptors such as "elevated" or "intermediate." The REACH-B score facilitates this conversation by grounding risk estimates in prospective cohort data rather than gestalt clinical judgment.

Patients with high REACH-B scores who are not yet on antiviral therapy can be shown the expected reduction in HBV DNA and ALT with effective treatment and the resulting decrease in HCC risk score, motivating therapy adherence. For patients already virally suppressed, the residual risk estimate (typically corresponding to the score calculated with HBV DNA = 0 and current ALT/age/sex/HBeAg) helps frame realistic expectations about ongoing surveillance necessity.

Validation Studies

Derivation and Internal Validation

The REACH-B score was derived from 3,584 REVEAL-HBV participants (after excluding those with cirrhosis at baseline) with a mean follow-up of 11.4 years, during which 115 participants developed HCC. Internal validation using bootstrap resampling demonstrated a c-statistic (area under the receiver operating characteristic curve) of 0.81 for 3-year HCC prediction and 0.79 for 10-year prediction, indicating good discriminatory performance.

External Validation

The REACH-B score has been externally validated in multiple independent cohorts:

• Korean validation cohort: A cohort of 1,505 Korean HBsAg-positive patients without cirrhosis confirmed the score's predictive accuracy, with a c-statistic of 0.77 for 10-year HCC prediction. The score performed equally well in HBeAg-positive and HBeAg-negative subgroups.
• Hong Kong CUHK cohort: External validation in a Hong Kong cohort of 1,026 non-cirrhotic HBV patients demonstrated a c-statistic of 0.76 and confirmed good calibration of absolute risk estimates across score strata.
• Western cohort studies: Several European and North American validation studies have reported somewhat lower discriminatory performance (c-statistics 0.68 to 0.74) in predominantly non-Asian cohorts, which may reflect differences in HBV genotype distribution (genotype A and D predominant in Western populations vs. genotype B and C in East Asia), different disease natural history, lower baseline prevalence of immune-active hepatitis, and longer duration of disease at cohort entry.
• Meta-analysis: A systematic review and meta-analysis of REACH-B validation studies confirmed pooled c-statistics of approximately 0.77 for 5-year and 0.75 for 10-year HCC prediction, supporting its broad applicability with the caveat of modest attenuation of performance outside East Asian populations.

Comparison with Other HBV-HCC Risk Scores

CU-HCC Score

The CU-HCC score incorporates age, albumin, bilirubin, HBV DNA, and cirrhosis status. Unlike REACH-B, it includes cirrhotic patients and albumin/bilirubin as liver function surrogates. It was derived from a clinical cohort at a tertiary referral center rather than a community-based cohort, which may introduce referral bias. Direct comparisons show broadly similar c-statistics to REACH-B for non-cirrhotic patients, with CU-HCC showing marginal superiority in cirrhotic patients (for whom REACH-B is not designed).

GAG-HCC Score

The GAG-HCC score uses age, sex, HBV DNA, core promoter mutation, and cirrhosis status. It incorporates viral genomic data (core promoter mutation A1762T/G1764A) that requires specialized testing not available in routine clinical practice, limiting its applicability compared to REACH-B, which relies entirely on standard laboratory tests.

PAGE-B Score

The Platelet-Age-Gender-HBV (PAGE-B) score was specifically developed for Caucasian European patients on antiviral therapy, incorporating platelet count, age, and sex. It is designed for treated rather than untreated patients and is therefore complementary to rather than competitive with REACH-B, which was derived in untreated community patients. The PAGE-B score has good performance in European cohorts for predicting HCC risk despite antiviral suppression, where REACH-B (requiring actual HBV DNA level) may underestimate residual risk in already-suppressed patients.

aMAP Score

The age-male-ALBI-platelet (aMAP) score incorporates the ALBI (albumin-bilirubin) index and platelet count as surrogate markers of liver fibrosis and synthetic function. The aMAP score performs well across different etiologies (HBV, HCV, NASH) and treatment status, making it more broadly applicable. However, it requires platelet count and full liver function panel, adding marginal complexity compared to REACH-B.

Natural History of Chronic HBV Infection

Phases of Chronic HBV Infection

• Phase 1 (HBeAg-positive chronic infection / Immune tolerance): HBeAg-positive, very high HBV DNA (>10⁷ IU/mL), normal or minimally elevated ALT, minimal liver inflammation on biopsy. Common in perinatally infected young adults. REACH-B scores in this phase may be paradoxically moderate despite very high HBV DNA, because ALT is low.
• Phase 2 (HBeAg-positive chronic hepatitis / Immune active): HBeAg-positive, high HBV DNA, elevated ALT, active inflammation and fibrosis on biopsy. This is the highest-risk phase for disease progression and HCC development. REACH-B scores are typically high in this phase.
• Phase 3 (HBeAg-negative chronic infection / Inactive carrier): HBsAg-positive, anti-HBe-positive, HBV DNA <2,000 IU/mL (often undetectable), persistently normal ALT, minimal inflammation. Low REACH-B scores; low HCC risk, though not zero, particularly in older patients or those with pre-existing fibrosis.
• Phase 4 (HBeAg-negative chronic hepatitis / Immune escape): HBsAg-positive, anti-HBe-positive, elevated HBV DNA driven by precore/basal core promoter mutant virus, fluctuating or persistently elevated ALT. REACH-B scores are intermediate to high; treatment is indicated.
• Phase 5 (HBsAg clearance): Loss of HBsAg with or without anti-HBs development (functional cure). REACH-B is not applicable after HBsAg loss. HCC risk drops substantially but persists at a low level (approximately 0.1 to 0.3% per year), particularly in patients who cleared HBsAg after age 50 or with pre-existing cirrhosis.

Impact of Antiviral Therapy on REACH-B Risk

Entecavir and tenofovir (TDF/TAF) are the preferred first-line antiviral agents for chronic HBV. Both achieve sustained HBV DNA suppression to undetectable levels in >95% of patients, normalize ALT in 70 to 80%, and have been shown in large retrospective and prospective studies to significantly reduce HCC incidence:

• A landmark Korean retrospective cohort study (Paik et al., NEJM 2021) demonstrated that entecavir or tenofovir therapy reduced HCC incidence by approximately 50% compared with untreated controls after propensity score matching.
• Regression of liver fibrosis and even cirrhosis reversal has been documented in 30 to 70% of patients achieving sustained virological suppression over 5 years.
• Residual HCC risk persists on antiviral therapy and is best predicted by pre-treatment fibrosis stage, age, and male sex, reinforcing that effective antiviral therapy shifts but does not eliminate the REACH-B risk profile.

For patients already on effective antiviral therapy with undetectable HBV DNA, recalculating the REACH-B score with HBV DNA = 0 points provides an estimate of residual risk based on non-modifiable (age, sex) and partially modifiable (ALT, HBeAg on-treatment) risk factors. This on-treatment REACH-B recalculation is a practical tool for individualized HCC surveillance planning in treated patients.

Integration with HCC Surveillance Guidelines

AASLD

AASLD guidelines recommend HCC surveillance with ultrasound every 6 months (with or without AFP) for all HBsAg-positive patients in the following groups: Asian men over 40, Asian women over 50, all cirrhotic HBV patients, individuals with a family history of HCC, and Africans over 20. The REACH-B score can supplement these age/sex criteria by quantifying risk in patients outside these demographic thresholds who nonetheless have high viral loads or active hepatitis.

EASL

EASL guidelines advocate for risk-stratified surveillance, recognizing that uniform surveillance of all HBsAg-positive patients is not cost-effective in low-prevalence settings. The REACH-B score is explicitly cited in EASL guidance as a validated tool for identifying patients at intermediate and high risk who benefit from regular surveillance.

APASL

APASL guidelines, addressing the highest-burden HBV populations, recommend surveillance for all HBsAg-positive adults over 40 and all cirrhotic patients, with the recognition that quantitative risk tools such as REACH-B provide meaningful additional precision. APASL explicitly endorses the use of REACH-B in non-cirrhotic patients to identify those at elevated risk who may warrant enhanced surveillance or prompt antiviral therapy initiation.

Special Populations and Considerations

Patients with HIV-HBV Co-infection

HIV co-infection accelerates HBV-related liver disease progression through impaired HBV-specific immune responses and, historically, through antiretroviral therapy hepatotoxicity. HCC incidence in HIV-HBV co-infected patients is approximately 2- to 3-fold higher than in HBV mono-infected patients at equivalent viral loads. The REACH-B score has not been formally validated in HIV co-infected patients, and it likely underestimates risk in this population.

Patients with HDV Co-infection

Hepatitis D virus (HDV) superinfection or co-infection with HBV markedly accelerates liver disease progression and dramatically increases HCC risk (approximately 3-fold compared with HBV alone). HDV status was not captured in the REVEAL-HBV cohort, and the REACH-B score should be interpreted cautiously in HDV-positive patients, with recognition that risk may be substantially underestimated.

Patients with NAFLD or Alcohol Use and HBV

Metabolic-associated fatty liver disease (MAFLD/NAFLD) and chronic alcohol use both potentiate HBV-related HCC risk through additive or synergistic mechanisms (oxidative stress, steatosis-induced inflammation, fibrosis acceleration). These cofactors are not captured by the REACH-B score. Clinicians should apply clinical judgment and consider comprehensive risk assessment alongside the REACH-B score in patients with significant metabolic comorbidities or alcohol use.

HBV Genotype Considerations

HBV comprises at least ten genotypes (A through J), with distinct geographic distributions and differences in disease natural history. Genotype C (prevalent in East Asia) is associated with delayed HBeAg seroconversion, higher rates of active hepatitis in middle-aged adults, and higher HCC risk compared with genotype B. Genotype B is associated with earlier HBeAg seroconversion and more favorable outcomes. The REVEAL-HBV cohort was predominantly genotype B and C; the applicability of REACH-B to genotypes A and D (prevalent in Western patients) is less well characterized, and slight performance attenuation in Western cohorts may partly reflect genotypic differences.

Patients Aged Over 65 or Under 30

The REACH-B score is validated for adults aged 30 to 65. Patients outside this age range were not included in the derivation cohort:

• Patients over 65 have increasing HCC risk with age, and the score will underestimate risk for this group by capping the age contribution at the 60 to 65 category. These patients should be counseled that risk estimates are a floor rather than a ceiling.
• Patients under 30 (particularly children and adolescents with perinatally acquired HBV) generally have very low absolute HCC risk in the short term, but long-term risk accumulates. The REACH-B score should not be applied to this group; individualized assessment is needed.

Limitations

• Non-cirrhotic patients only: The REACH-B score was derived exclusively from patients without cirrhosis at baseline. Patients with compensated or decompensated cirrhosis have substantially higher baseline HCC risk (annual incidence 2 to 8%) that exceeds what REACH-B estimates, and they should be placed on unconditional surveillance regardless of their REACH-B score.
• Single baseline measurement: The score uses a single time-point snapshot of HBV DNA and ALT. In patients with fluctuating viremia (common in HBeAg-negative chronic hepatitis B), a single measurement may not accurately represent the long-term risk profile. Serial measurements over 6 to 12 months, or use of the worst (highest) values, may better reflect risk.
• East Asian derivation cohort: The REVEAL-HBV cohort was drawn from a Taiwanese community-based population predominantly infected with HBV genotypes B and C, with high endemicity and predominantly perinatal/early childhood acquisition. Performance is modestly attenuated in Western cohorts, and clinicians should apply additional clinical judgment in non-Asian patients.
• Does not incorporate fibrosis stage: Liver fibrosis stage (assessed by biopsy, elastography, or non-invasive biomarker indices) is a strong predictor of HCC risk independent of the REACH-B variables. Patients with advanced fibrosis (F3) or early cirrhosis not yet detectable as clinical cirrhosis have higher risk than REACH-B alone predicts. Combining REACH-B with a fibrosis assessment tool (e.g., FIB-4, liver stiffness measurement) may improve risk stratification.
• Does not capture family history: First-degree family history of HCC is an independent risk factor for HCC in HBV carriers, conferring approximately 2-fold higher risk. Family history is not incorporated into the REACH-B score.
• Not designed for on-treatment monitoring of all outcomes: While REACH-B can be recalculated using on-treatment values, it was not prospectively validated in treated cohorts. The PAGE-B and modified PAGE-B (mPAGE-B) scores were specifically developed for treated patients and may be more appropriate for HCC risk estimation in patients receiving antiviral therapy.
• This calculator is for educational and clinical support use only. HCC risk assessment and decisions regarding antiviral therapy initiation, surveillance modality, and frequency should be made by a specialist in hepatology or gastroenterology with access to the complete clinical history, liver function, imaging, and virological data.